Save the date






2025 LAUSANNE PROTEOMICS DAY

Wednesday 7th May | 09:30 - 12:30

Auditoire Paternot - Agora Cancer Research Center Rue du Bugnon 25A, 1005 Lausanne

Join us for the Lausanne Proteomics Day, co-hosted by the Imaging and Mass Cytometry Platform at the **Agora Cancer Research Center** and **Standard BioTools**. This seminar features in-depth presentations from experts at CHUV, EPFL, and industry, highlighting how high-plex proteomic and cytometric technologies are advancing translational research. Explore how high-dimensional flow cytometry enables deep immune profiling at the single-cell level, how Imaging Mass Cytometry (IMC) reveals spatial tissue organization and cellular interactions, and how high-throughput proteomics and antibody profiling are unlocking new opportunities in biomarker discovery and disease mechanism studies. These innovative tools are already integrated into a wide range of clinical and preclinical projects — come discover how they are shaping the future of precision medicine, right here in Lausanne.









Register live



Questions? Please contact: Hind | hind.hachemi@standardbio.com

Program





11:30

2025 LAUSANNE PROTEOMICS DAY

REGISTRATION		09:00
	From High Plex Flow Cytometry to Whole Slide Imaging Mass Cytometry Dr. Melissa Klug, Field Applications Scientist, Cytometry and Tissue Imaging, Standard BioTools	09:30
	Biomarker Identification in Personalized Cancer Cell Therapy M.Sc Naoill Abdellaoui, Imaging and Mass Cytometry Core Facility Manager, Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV)	09:50
	Unveiling Clinical Discoveries with Al Deep Learning and Unsupervised IMC Analyses Dr. Maxime Petit, Postdoctoral researcher, EPFL SV ISREC - UPRAD	10:15
	Unlocking the Power of High Multiplex Proteomics with SomaScan Dr. Gary Prescott, Field Application Scientist, EMEA Standard BioTools	10:40
	& Dr. Eshita Mutt, Bioinformatics Application Specialist (EMEA region), Global Scientific & Data Engagement team, Standard Biotools	
	Serum Proteotypes Identified from Large-Scale Proteomics Predict Response to Immunotherapy after Chemoradiotherapy in Patients with Limited Disease Small-Cell Lung Cancer Dr. Krisztian Homicsko, MD-PhD, PD/MERc, Chef de clinique/Oberarzt, Département d'Oncologie – CHUV	11:00

For Research Use Only. Not for use in diagnostic procedures.

APERITIF